Invesco
RYTM icon

Invesco’s Rhythm Pharmaceuticals RYTM Stock Holding History

Invesco’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60.3M Buy
543,271
+178,965
+49% +$16.2M ﹤0.01% 1060
2026
Q1 		$31.7M Buy
364,306
+73,156
+25% +$7.11M ﹤0.01% 1252
2025
Q4 		$31.2M Buy
291,150
+147,595
+103% +$15.7M ﹤0.01% 1254
2025
Q3 		$14.5M Buy
143,555
+74,631
+108% +$6.93M ﹤0.01% 1614
2025
Q2 		$4.36M Sell
68,924
-192,978
-74% -$11.8M ﹤0.01% 2261
2025
Q1 		$13.9M Sell
261,902
-40,944
-14% -$2.27M ﹤0.01% 1609
2024
Q4 		$17M Buy
302,846
+38,429
+15% +$2.12M ﹤0.01% 1579
2024
Q3 		$13.9M Sell
264,417
-12,283
-4% -$589K ﹤0.01% 1665
2024
Q2 		$11.4M Buy
276,700
+188,495
+214% +$7.52M ﹤0.01% 1729
2024
Q1 		$3.82M Sell
88,205
-47,526
-35% -$2.08M ﹤0.01% 2383
2023
Q4 		$6.24M Buy
135,731
+107,357
+378% +$3.39M ﹤0.01% 2126
2023
Q3 		$650K Buy
28,374
+98
+0.3% +$2.19K ﹤0.01% 3072
2023
Q2 		$466K Buy
+28,276
New +$510K ﹤0.01% 3277
2023
Q1 		– Sell
-334,273
Closed -$9.73M – 3989
2022
Q4 		$9.73M Buy
+334,273
New +$8.59M ﹤0.01% 1864
2022
Q2 		– Sell
-16,507
Closed -$190K – 4127
2022
Q1 		$190K Sell
16,507
-7,741
-32% -$67.9K ﹤0.01% 3779
2021
Q4 		$243K Sell
24,248
-3,085
-11% -$34.7K ﹤0.01% 3707
2021
Q3 		$357K Buy
27,333
+2,025
+8% +$30.9K ﹤0.01% 3583
2021
Q2 		$495K Buy
25,308
+8,101
+47% +$168K ﹤0.01% 3429
2021
Q1 		$366K Buy
17,207
+2,595
+18% +$75.3K ﹤0.01% 3467
2020
Q4 		$434K Buy
14,612
+4,648
+47% +$118K ﹤0.01% 3267
2020
Q3 		$216K Sell
9,964
-170
-2% -$3.9K ﹤0.01% 3438
2020
Q2 		$226K Sell
10,134
-993
-9% -$19.4K ﹤0.01% 3433
2020
Q1 		$169K Buy
+11,127
New +$199K ﹤0.01% 3457

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Invesco's RYTM Position: Q2 2026 in Review

Invesco increased its Rhythm Pharmaceuticals (RYTM) stake by 49% in Q2 2026, buying an estimated $16.2M and bringing the position to 543,271 shares worth $60.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1060.

Invesco first reported a position in RYTM in Q1 2020 and has held it in 23 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Invesco held 543,271 shares of Rhythm Pharmaceuticals worth $60.3M as of Q2 2026.
  • Invesco bought 178,965 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $16.2M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #1060 holding.
  • Invesco first reported a position in Rhythm Pharmaceuticals in Q1 2020 and has held it in 23 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.